📣 VC round data is live. Check it out!

Brightgene Bio-medical Valuation Multiples

Discover revenue and EBITDA valuation multiples for Brightgene Bio-medical and similar public comparables like Virbac, Organon, Edgewise Therapeutics, Laboratorios Rovi and more.

Brightgene Bio-medical Overview

About Brightgene Bio-medical

Brightgene Bio-medical Technology Co Ltd is a pharmaceutical company engaged in research, development and production of new drugs and high-end generic drugs. The company develops macrolides, peptides, polysaccharides, heterocycles, azoles, azines, phenyl ethers, tetracyclines, and production of non-pharmaceutical macrolides, peptides, polysaccharides, heterocycles, azoles, azines, benzene Ethers, tetracyclines.


Founded

2001

HQ

China

Employees

N/A

Financials (LTM)

Revenue: $182M
EBITDA: $52M

EV

$4B

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Brightgene Bio-medical Financials

Brightgene Bio-medical reported last 12-month revenue of $182M and EBITDA of $52M.

In the same LTM period, Brightgene Bio-medical generated $92M in gross profit, $52M in EBITDA, and $10M in net income.

Revenue (LTM)


Brightgene Bio-medical P&L

In the most recent fiscal year, Brightgene Bio-medical reported revenue of $180M and EBITDA of $36M.

Brightgene Bio-medical is profitable as of last fiscal year, with gross margin of 51%, EBITDA margin of 20%, and net margin of 4%.

See analyst estimates for Brightgene Bio-medical
LTMLast FY202320242025202620272028
Revenue$182M$180M$174M$189M$180M
Gross Profit$92M$92M$97M$109M$92M
Gross Margin50%51%56%58%51%
EBITDA$52M$36M$46M$47M$35M
EBITDA Margin28%20%26%25%19%
EBIT Margin2%9%22%20%9%
Net Profit$10M$8M$30M$28M$8M
Net Margin6%4%17%15%4%
Net Debt-$79M---

Financial data powered by Morningstar, Inc.

Brightgene Bio-medical Stock Performance

Brightgene Bio-medical has current market cap of $4B, and enterprise value of $4B.

Market Cap Evolution


Brightgene Bio-medical's stock price is $8.12.

Brightgene Bio-medical share price decreased by 12.0% in the last 30 days, and increased by 8.2% in the last year.

Brightgene Bio-medical has an EPS (earnings per share) of $0.02.

See more trading valuation data for Brightgene Bio-medical
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$4B$4B-3.6%-12.0%20.8%8.2%$0.02

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Brightgene Bio-medical Valuation Multiples

Brightgene Bio-medical trades at 20.8x EV/Revenue multiple, and 73.3x EV/EBITDA.

See NTM and 2027E valuation multiples for Brightgene Bio-medical

EV / Revenue (LTM)


Brightgene Bio-medical Financial Valuation Multiples

As of May 27, 2026, Brightgene Bio-medical has market cap of $4B and EV of $4B.

Brightgene Bio-medical has a P/E ratio of 347.2x.

LTMLast FY202320242025202620272028
EV/Revenue20.8x21.0x21.8x20.1x21.0x
EV/EBITDA73.3x103.9x82.7x80.1x108.9x
EV/EBITn/m233.5x101.4x102.6x233.5x
EV/Gross Profit41.1x41.4x39.1x34.9x41.4x
P/En/mn/m118.7x127.1xn/m
EV/FCF-(200.7x)(123.1x)n/m(200.7x)

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Brightgene Bio-medical Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Brightgene Bio-medical Margins & Growth Rates

Brightgene Bio-medical grew revenue by 5% and EBITDA by 104% in the last fiscal year.

In the most recent fiscal year, Brightgene Bio-medical reported gross margin of 51%, EBITDA margin of 20%, and net margin of 4%.

See estimated margins and future growth rates for Brightgene Bio-medical

Brightgene Bio-medical Margins

Last FY202420252026202720282029
Gross Margin51%58%51%50%
EBITDA Margin20%25%19%39%
EBIT Margin9%20%9%4%
Net Margin4%15%4%7%
FCF Margin(10%)(1%)(10%)-

Brightgene Bio-medical Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
Revenue Growth5%9%(5%)5%
Gross Profit Growth3%12%(16%)3%
EBITDA Growth104%3%(26%)114%
EBIT Growth(56%)(1%)(56%)(56%)
Net Profit Growth69%(7%)(71%)69%
FCF Growth-(94%)1002%-

Data powered by FactSet, Inc. and Morningstar, Inc.

Brightgene Bio-medical Operational KPIs

Brightgene Bio-medical's Rule of 40 is 44% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Brightgene Bio-medical's Rule of X is 52% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Access forward-looking KPIs for Brightgene Bio-medical
LTMLast FY202320242025202620272028
Rule of 4064%44%---
Bessemer Rule of X117%52%---
S&M Expenses to Revenue6%6%5%5%5%
G&A Expenses to Revenue12%12%4%4%4%
R&D Expenses to Revenue24%25%21%23%25%
Opex to Revenue-42%34%38%42%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Brightgene Bio-medical Competitors

Brightgene Bio-medical competitors include Virbac, Organon, Edgewise Therapeutics, Laboratorios Rovi, Erasca, Zealand Pharma, Viking Therapeutics, Zhejiang Huahai, ACADIA Pharmaceuticals and Genscript Biotech.

Most Brightgene Bio-medical public comparables operate across Biopharmaceuticals, Contract Research & Manufacturing, BioTech and DeepTech.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Virbac2.2x2.2x11.2x10.8x
Organon1.8x1.8x5.8x5.8x
Edgewise Therapeutics--(16.0x)(14.8x)
Laboratorios Rovi4.0x4.1x14.9x13.9x
Erasca--(25.7x)(15.7x)
Zealand Pharma0.9x1.1x1.2x1.8x
Viking Therapeutics--(7.6x)(6.1x)
Zhejiang Huahai3.5x3.5x18.0x16.9x

This data is available for Pro users. Sign up to see all Brightgene Bio-medical competitors and their valuation data.

Start Free Trial

Brightgene Bio-medical Funding History

Before going public, Brightgene Bio-medical raised $81M in total equity funding, across 1 round.


Brightgene Bio-medical Funding Rounds

DateStageRaised FromRaisedValuationRev. MultipleDeal Summary
Jan-19Undisclosed stageGF Qianhe Investment; Highlight Capital; HSG; China Coal Xinji Energy$81M--

Brightgene Bio-medical Investment Activity

Brightgene Bio-medical has invested in 2 companies to date.

Latest investment by Brightgene Bio-medical was on July 2nd 2020. Brightgene Bio-medical invested in Citryll in their $22M Series B round (EV/Revenue multiple of ).

See VC round multiples

Latest Investments by Brightgene Bio-medical

Citryll
DNALite Therapeutics
Description
Citryll is a biopharmaceutical company developing PAD4 inhibitors targeting NETosis for autoimmune diseases including lupus, vasculitis, rheumatoid arthritis, pulmonary fibrosis, and sepsis-related organ damage. Oss-headquartered in the Netherlands since 2015, the firm advances small-molecule drugs that block peptidylarginine deiminase enzymes to reduce inflammation and tissue injury.
DNALite Therapeutics is a preclinical biotechnology company developing oral lipid nanoparticles for mRNA and plasmid DNA delivery to the gastrointestinal tract. Based in Israel, the firm engineers intestine-specific secretion of therapeutic proteins into the bloodstream, converting injectables like insulin into pills. Founded in 2019, DNALite targets inflammatory bowel disease and metabolic disorders, with lead candidates demonstrating oral bioavailability in animal models.
HQ CountryNetherlandsUnited States
HQ City
Oss
San Francisco, CA
Deal Date2 Jul 20208 Aug 2018
RoundSeries BSeed
Raised$22M$2M
InvestorsBioGeneration Ventures; BOM; Brightgene Bio-medical; ModiQuest B.V.; Seventure PartnersBerkeley Catalyst Fund (BCF); Blue Bear Ventures; Brightgene Bio-medical; SOSV; SVE Capital; University of California Berkeley
Valuationundisclosedundisclosed
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all Brightgene Bio-medical investments and their VC round multiples.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Brightgene Bio-medical

Who are competitors of Brightgene Bio-medical?Brightgene Bio-medical main competitors include Virbac, Organon, Edgewise Therapeutics, Laboratorios Rovi, Erasca, Zealand Pharma, Viking Therapeutics, Zhejiang Huahai, ACADIA Pharmaceuticals, Genscript Biotech.

See public comps similar to Brightgene Bio-medical

Lists including Brightgene Bio-medical

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial